Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript March 3, 2025
Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.16.
Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. [Operator Instructions] I would now like to turn the conference over...
